FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1777507583> ?p ?o ?g. }

• W1777507583 endingPage "2000" @default.
• W1777507583 startingPage "1993" @default.
• W1777507583 abstract "To evaluate attainment of diabetes-related treatment goals with canagliflozin, a sodium glucose co-transporter 2 inhibitor, versus placebo in patients with type 2 diabetes mellitus (T2DM).Data were pooled from four 26-week, placebo-controlled, Phase 3 studies of patients with T2DM (N = 2313). Goal attainment with canagliflozin 100 and 300 mg versus placebo was evaluated in the overall population, and in subgroups based on age and sex, at baseline and Week 26.ClinicalTrials.gov NCT01081834, NCT01106677, NCT01106625, NCT01106690.Proportion of patients achieving hemoglobin A1C (A1C) < 7.0% and ≤ 6.5%, systolic blood pressure (SBP) < 140 and < 130 mmHg, diastolic blood pressure (DBP) < 90 and < 80 mmHg, low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL (2.6 mmol/L), high-density lipoprotein cholesterol (HDL-C) ≥ 40 mg/dL (1.0 mmol/L), and the composite endpoint of A1C < 7.0%, BP < 130/80 mmHg, and LDL-C <100 mg/dL (2.6 mmol/L) at baseline and Week 26, and proportion with body weight reduction ≥ 5% at Week 26.At baseline, similar proportions of patients met diabetes-related treatment goals across groups. At Week 26, a greater proportion of patients achieved A1C, SBP, DBP, and HDL-C goals with canagliflozin 100 and 300 mg compared with placebo. More patients achieved body weight reduction of ≥ 5% with canagliflozin 100 and 300 mg versus placebo at Week 26. Fewer patients had LDL-C < 100 mg/dL (2.6 mmol/L) at Week 26 with canagliflozin 100 and 300 mg versus placebo. Canagliflozin 100 and 300 mg also provided better attainment of the composite endpoint of A1C <7.0%, BP < 130/80 mmHg, and LDL-C < 100 mg/dL (2.6 mmol/L) compared with placebo. Attainment of diabetes-related treatment goals was generally similar regardless of age and sex. Key limitations of this analysis include the selection of specific treatment targets that may not be reflective of all patient experiences, the non-prespecified, post hoc nature of the analysis, and the short duration of studies included in the pooled population.Canagliflozin was associated with better attainment of diabetes-related treatment goals compared with placebo, and was generally well tolerated at 26 weeks." @default.
• W1777507583 created "2016-06-24" @default.
• W1777507583 creator A5002858323 @default.
• W1777507583 creator A5011865990 @default.
• W1777507583 creator A5026752543 @default.
• W1777507583 creator A5031542137 @default.
• W1777507583 creator A5032297044 @default.
• W1777507583 creator A5053469409 @default.
• W1777507583 creator A5070289715 @default.
• W1777507583 date "2015-09-28" @default.
• W1777507583 modified "2023-10-10" @default.
• W1777507583 title "Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials" @default.
• W1777507583 cites W1532333918 @default.
• W1777507583 cites W1968145432 @default.
• W1777507583 cites W1974115114 @default.
• W1777507583 cites W1981671332 @default.
• W1777507583 cites W1982905493 @default.
• W1777507583 cites W1984513597 @default.
• W1777507583 cites W1987553321 @default.
• W1777507583 cites W1996837305 @default.
• W1777507583 cites W2004014076 @default.
• W1777507583 cites W2007221722 @default.
• W1777507583 cites W2024992738 @default.
• W1777507583 cites W2031333151 @default.
• W1777507583 cites W2038270027 @default.
• W1777507583 cites W2045790951 @default.
• W1777507583 cites W2047553605 @default.
• W1777507583 cites W2068171948 @default.
• W1777507583 cites W2074989651 @default.
• W1777507583 cites W2077038286 @default.
• W1777507583 cites W2083379012 @default.
• W1777507583 cites W2101244337 @default.
• W1777507583 cites W2120919346 @default.
• W1777507583 cites W2124234371 @default.
• W1777507583 cites W2130570549 @default.
• W1777507583 cites W2134932941 @default.
• W1777507583 cites W2147222003 @default.
• W1777507583 cites W2148385940 @default.
• W1777507583 cites W2160088494 @default.
• W1777507583 cites W2166823746 @default.
• W1777507583 cites W2167984652 @default.
• W1777507583 cites W2168926920 @default.
• W1777507583 doi "https://doi.org/10.1185/03007995.2015.1082991" @default.
• W1777507583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26373629" @default.
• W1777507583 hasPublicationYear "2015" @default.
• W1777507583 type Work @default.
• W1777507583 sameAs 1777507583 @default.
• W1777507583 citedByCount "10" @default.
• W1777507583 countsByYear W17775075832016 @default.
• W1777507583 countsByYear W17775075832017 @default.
• W1777507583 countsByYear W17775075832018 @default.
• W1777507583 countsByYear W17775075832019 @default.
• W1777507583 countsByYear W17775075832021 @default.
• W1777507583 countsByYear W17775075832023 @default.
• W1777507583 crossrefType "journal-article" @default.
• W1777507583 hasAuthorship W1777507583A5002858323 @default.
• W1777507583 hasAuthorship W1777507583A5011865990 @default.
• W1777507583 hasAuthorship W1777507583A5026752543 @default.
• W1777507583 hasAuthorship W1777507583A5031542137 @default.
• W1777507583 hasAuthorship W1777507583A5032297044 @default.
• W1777507583 hasAuthorship W1777507583A5053469409 @default.
• W1777507583 hasAuthorship W1777507583A5070289715 @default.
• W1777507583 hasConcept C126322002 @default.
• W1777507583 hasConcept C134018914 @default.
• W1777507583 hasConcept C142724271 @default.
• W1777507583 hasConcept C204787440 @default.
• W1777507583 hasConcept C27081682 @default.
• W1777507583 hasConcept C2777180221 @default.
• W1777507583 hasConcept C2777451236 @default.
• W1777507583 hasConcept C2908647359 @default.
• W1777507583 hasConcept C2910068830 @default.
• W1777507583 hasConcept C555293320 @default.
• W1777507583 hasConcept C71924100 @default.
• W1777507583 hasConcept C84393581 @default.
• W1777507583 hasConcept C90924648 @default.
• W1777507583 hasConcept C99454951 @default.
• W1777507583 hasConceptScore W1777507583C126322002 @default.
• W1777507583 hasConceptScore W1777507583C134018914 @default.
• W1777507583 hasConceptScore W1777507583C142724271 @default.
• W1777507583 hasConceptScore W1777507583C204787440 @default.
• W1777507583 hasConceptScore W1777507583C27081682 @default.
• W1777507583 hasConceptScore W1777507583C2777180221 @default.
• W1777507583 hasConceptScore W1777507583C2777451236 @default.
• W1777507583 hasConceptScore W1777507583C2908647359 @default.
• W1777507583 hasConceptScore W1777507583C2910068830 @default.
• W1777507583 hasConceptScore W1777507583C555293320 @default.
• W1777507583 hasConceptScore W1777507583C71924100 @default.
• W1777507583 hasConceptScore W1777507583C84393581 @default.
• W1777507583 hasConceptScore W1777507583C90924648 @default.
• W1777507583 hasConceptScore W1777507583C99454951 @default.
• W1777507583 hasIssue "11" @default.
• W1777507583 hasLocation W17775075831 @default.
• W1777507583 hasLocation W17775075832 @default.
• W1777507583 hasOpenAccess W1777507583 @default.
• W1777507583 hasPrimaryLocation W17775075831 @default.
• W1777507583 hasRelatedWork W2327349099 @default.
• W1777507583 hasRelatedWork W2373302420 @default.
• W1777507583 hasRelatedWork W2405267214 @default.

• next